Ovid Therapeutics Inc. - Common Stock (OVID)

Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics.

OVID stock results show that Ovid Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Biotech stocks can be extremely challenging because it takes a long time to bring a therapy to market. Here are some biotech stocks to sell.

Investors wondering if the stock market is closed on Juneteenth 2024 have come to the right place as we have an answer to that question!

Archer Aviation stock is down on Monday after the company alerted ACHR investors to a new MOU signed with Signature Aviation.

The Aaron's Company stock is up on Monday after it announced a take-private deal that values AAN shares at $10.10 each.

Ovid Therapeutics stock is down on Monday with heavy trading of OVID shares after the company reported a failed Phase3 clinical trial.

Takeda Pharmaceutical reveals Phase 3 study data for Soticlestat (TAK-935) in treating Dravet and Lennox-Gastaut syndromes. In 2021, Ovid Therapeutics out licensed the drug.

Steer clear of these three penny stocks to sell that are plagued by financial instability and mounting losses.

Although the concept of penny stocks to buy is extremely risky, these ideas have the advantage of analysts’ positive assessments.

OVID stock results show that Ovid Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.